Chinese expert consensus on precision diagnosis, treatment, and multidisciplinary management of immune platelet transfusion refractoriness (2026 Edition)
10.13303/j.cjbt.issn.1004-549x.2026.02.001
- VernacularTitle:免疫性血小板输注无效精准诊疗与多学科管理中国专家共识（2026年版）
- Collective Name:Clinical Transfusion Medicine Professional Committee of the Chinese Society of Blood Transfusion
- Publication Type:Journal Article
- Keywords:
platelet transfusion refractoriness;
HLA antibody;
HPA antibody;
crossmatching;
restricted platelet transfusion;
multidisciplinary management
- From:
Chinese Journal of Blood Transfusion
2026;39(2):157-167
- CountryChina
- Language:Chinese
-
Abstract:
Patients with thrombocytopenia or platelet dysfunction often require platelet transfusions to improve their condition. However, some patients develop platelet transfusion refractoriness (PTR) after multiple transfusions, characterized by a lack of clinical improvement and/or failure to achieve the expected platelet count increment after two consecutive transfusions of adequate, fresh, ABO-compatible platelets. This poses significant challenges for clinical management. Transfusion of crossmatch-compatible platelets is an effective strategy for PTR caused by immune factors, yet current practices for platelet matching and the selection of compatible platelets require standardization. To address this, the Clinical Transfusion Medicine Professional Committee of the Chinese Society of Blood Transfusion has organized domestic experts to compile the Chinese Expert Consensus on Precision Diagnosis, Treatment, and Multidisciplinary Management of Immune Platelet Transfusion Refractoriness (2026 Edition). This consensus covers core aspects including platelet antibody detection, matching methodologies, procedural workflows, and multidisciplinary management (involving transfusion department, hematology department, blood center, etc.), aiming to enhance platelet transfusion efficacy, conserve blood resources, and ensure the safety of clinical blood use.
